Response analysis among the intention-to-treat population
| Response, n (%) . | Ibrutinib + CIT (n = 202) . | Placebo + CIT (n = 201) . |
|---|---|---|
| ORR | 185 (91.6) | 182 (90.5) |
| Best response | ||
| CR | 111 (55.0) | 101 (50.2) |
| PR | 74 (36.6) | 81 (40.3) |
| SD | 5 (2.5) | 11 (5.5) |
| PD | 4 (2.0) | 2 (1.0) |
| Unknown | 8 (4.0) | 6 (3.0) |
| Response, n (%) . | Ibrutinib + CIT (n = 202) . | Placebo + CIT (n = 201) . |
|---|---|---|
| ORR | 185 (91.6) | 182 (90.5) |
| Best response | ||
| CR | 111 (55.0) | 101 (50.2) |
| PR | 74 (36.6) | 81 (40.3) |
| SD | 5 (2.5) | 11 (5.5) |
| PD | 4 (2.0) | 2 (1.0) |
| Unknown | 8 (4.0) | 6 (3.0) |
PR, partial response; SD, stable disease.